Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 208

1.

Correction of bleeding in experimental severe hemophilia A by systemic delivery of factor VIII-encoding mRNA.

Russick J, Delignat S, Milanov P, Christophe O, Boros G, Denis CV, Lenting PJ, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Jul 9. pii: haematol.2018.210583. doi: 10.3324/haematol.2018.210583. [Epub ahead of print]

2.

Sequence features of variable region determining physicochemical properties and polyreactivity of therapeutic antibodies.

Lecerf M, Kanyavuz A, Lacroix-Desmazes S, Dimitrov JD.

Mol Immunol. 2019 Aug;112:338-346. doi: 10.1016/j.molimm.2019.06.012. Epub 2019 Jun 26.

PMID:
31254774
3.

Risk stratification integrating genetic data for factor VIII inhibitor development in patients with severe hemophilia A.

Bachelet D, Albert T, Mbogning C, Hässler S, Zhang Y, Schultze-Strasser S, Repessé Y, Rayes J, Pavlova A, Pezeshkpoor B, Liphardt K, Davidson JE, Hincelin-Méry A, Dönnes P, Lacroix-Desmazes S, Königs C, Oldenburg J, Broët P; ABIRISK consortium.

PLoS One. 2019 Jun 13;14(6):e0218258. doi: 10.1371/journal.pone.0218258. eCollection 2019.

4.

Natural Antibodies: from First-Line Defense Against Pathogens to Perpetual Immune Homeostasis.

Maddur MS, Lacroix-Desmazes S, Dimitrov JD, Kazatchkine MD, Bayry J, Kaveri SV.

Clin Rev Allergy Immunol. 2019 Jun 3. doi: 10.1007/s12016-019-08746-9. [Epub ahead of print] Review.

PMID:
31161341
5.

Use of cysteine as a spectroscopic probe for determination of heme-scavenging capacity of serum proteins and whole human serum.

Noé R, Bozinovic N, Lecerf M, Lacroix-Desmazes S, Dimitrov JD.

J Pharm Biomed Anal. 2019 Aug 5;172:311-319. doi: 10.1016/j.jpba.2019.05.013. Epub 2019 May 7.

6.

Anti-inflammatory activity of intravenous immunoglobulin through scavenging of heme.

Wiatr M, Merle NS, Boudhabhay I, Poillerat V, Rossini S, Lecerf M, Kaveri SV, Lacroix-Desmazes S, Roumenina LT, Dimitrov JD.

Mol Immunol. 2019 Jul;111:205-208. doi: 10.1016/j.molimm.2019.04.020. Epub 2019 May 10.

7.

Breaking the law: unconventional strategies for antibody diversification.

Kanyavuz A, Marey-Jarossay A, Lacroix-Desmazes S, Dimitrov JD.

Nat Rev Immunol. 2019 Jun;19(6):355-368. doi: 10.1038/s41577-019-0126-7. Review.

PMID:
30718829
8.

Role of factor VIII-binding capacity of endogenous von Willebrand factor in the development of factor VIII inhibitors in patients with severe hemophilia A.

Repessé Y, Costa C, Palla R, Moshai EF, Borel-Derlon A, D'Oiron R, Rothschild C, El-Beshlawy A, Elalfy M, Ramanan V, Eshghi P, Oldenburg J, Pavlova A, Rosendaal FR, Peyvandi F, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 Aug;104(8):e369-e372. doi: 10.3324/haematol.2018.212001. Epub 2019 Jan 31. No abstract available.

9.

The nitrone spin trap 5,5‑dimethyl‑1‑pyrroline N‑oxide binds to toll-like receptor-2-TIR-BB-loop domain and dampens downstream inflammatory signaling.

Muñoz MD, Gutierrez LJ, Delignat S, Russick J, Gomez Mejiba SE, Lacroix-Desmazes S, Enriz RD, Ramirez DC.

Biochim Biophys Acta Mol Basis Dis. 2019 Jun 1;1865(6):1152-1159. doi: 10.1016/j.bbadis.2019.01.005. Epub 2019 Jan 23.

PMID:
30684639
10.

Prevention of the anti-factor VIII memory B-cell response by inhibition of Bruton tyrosine kinase in experimental hemophilia A.

Delignat S, Russick J, Gangadharan B, Rayes J, Ing M, Voorberg J, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2019 May;104(5):1046-1054. doi: 10.3324/haematol.2018.200279. Epub 2018 Dec 13.

11.

Pathogenic immune response to therapeutic factor VIII: exacerbated response or failed induction of tolerance?

Varthaman A, Lacroix-Desmazes S.

Haematologica. 2019 Feb;104(2):236-244. doi: 10.3324/haematol.2018.206383. Epub 2018 Dec 4. Review.

12.

Catalytic antibodies in patients with systemic lupus erythematosus.

Pradhan V, Pandit P, Surve P, Lecerf M, Rajadhyaksha A, Nadkar M, Khadilkar PV, Chougule DA, Naigaonkar AA, Lacroix-Desmazes S, Bayry J, Ghosh K, Kaveri SV.

Eur J Rheumatol. 2018 Sep;5(3):173-178. doi: 10.5152/eurjrheum.2018.17194. Epub 2018 Aug 7.

13.

Inhibitor Formation in Congenital Hemophilia A: an Immunological Perspective.

Delignat S, Rayes J, Russick J, Kaveri SV, Lacroix-Desmazes S; ABIRISK consortium.

Semin Thromb Hemost. 2018 Sep;44(6):517-530. doi: 10.1055/s-0038-1657777. Epub 2018 Jun 4. Review.

PMID:
29864775
14.

Biochemical characterization and immunogenicity of Neureight, a recombinant full-length factor VIII produced by fed-batch process in disposable bioreactors.

Delignat S, Peyron I, El Ghazaly M, V Kaveri S, Rohde J, Mueller F, Lacroix-Desmazes S.

Cell Immunol. 2018 Sep;331:22-29. doi: 10.1016/j.cellimm.2018.05.002. Epub 2018 May 5.

PMID:
29751951
15.

Enzymatically oxidized phospholipids restore thrombin generation in coagulation factor deficiencies.

Slatter DA, Percy CL, Allen-Redpath K, Gajsiewicz JM, Brooks NJ, Clayton A, Tyrrell VJ, Rosas M, Lauder SN, Watson A, Dul M, Garcia-Diaz Y, Aldrovandi M, Heurich M, Hall J, Morrissey JH, Lacroix-Desmazes S, Delignat S, Jenkins PV, Collins PW, O'Donnell VB.

JCI Insight. 2018 Mar 22;3(6). pii: 98459. doi: 10.1172/jci.insight.98459.

16.

Absence of a neutralizing antibody response to humanized cobra venom factor in mice.

Ing M, Hew BE, Fritzinger DC, Delignat S, Lacroix-Desmazes S, Vogel CW, Rayes J.

Mol Immunol. 2018 May;97:1-7. doi: 10.1016/j.molimm.2018.02.018. Epub 2018 Mar 8.

PMID:
29525557
17.

Oxidation of factor VIII increases its immunogenicity in mice with severe hemophilia A.

Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Srivastava A, Kaveri SV, Lacroix-Desmazes S.

Cell Immunol. 2018 Mar;325:64-68. doi: 10.1016/j.cellimm.2018.01.008. Epub 2018 Jan 31.

PMID:
29395036
18.

CD4 T cells specific for factor VIII are present at high frequency in healthy donors and comprise naïve and memory cells.

Meunier S, Menier C, Marcon E, Lacroix-Desmazes S, Maillère B.

Blood Adv. 2017 Sep 25;1(21):1842-1847. doi: 10.1182/bloodadvances.2017008706. eCollection 2017 Sep 26.

19.

Complement C3 is a novel modulator of the anti-factor VIII immune response.

Rayes J, Ing M, Delignat S, Peyron I, Gilardin L, Vogel CW, Fritzinger DC, Frémeaux-Bacchi V, Kaveri SV, Roumenina LT, Lacroix-Desmazes S.

Haematologica. 2018 Feb;103(2):351-360. doi: 10.3324/haematol.2017.165720. Epub 2017 Nov 16.

20.

The ADAMTS131239-1253 peptide is a dominant HLA-DR1-restricted CD4+ T-cell epitope.

Gilardin L, Delignat S, Peyron I, Ing M, Lone YC, Gangadharan B, Michard B, Kherabi Y, Sharma M, Pashov A, Latouche JB, Hamieh M, Toutirais O, Loiseau P, Galicier L, Veyradier A, Kaveri S, Maillère B, Coppo P, Lacroix-Desmazes S.

Haematologica. 2017 Nov;102(11):1833-1841. doi: 10.3324/haematol.2015.136671. Epub 2017 Jul 27.

21.

Methods for Posttranslational Induction of Polyreactivity of Antibodies.

Lecerf M, Jarossay A, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Methods Mol Biol. 2017;1643:135-145. doi: 10.1007/978-1-4939-7180-0_10.

PMID:
28667534
22.

Impact of Antigen Density on the Binding Mechanism of IgG Antibodies.

Hadzhieva M, Pashov AD, Kaveri S, Lacroix-Desmazes S, Mouquet H, Dimitrov JD.

Sci Rep. 2017 Jun 19;7(1):3767. doi: 10.1038/s41598-017-03942-z.

23.

Monoepitopic anti-FVIII T-cell response.

Lacroix-Desmazes S, Maillere B.

Blood. 2016 Oct 20;128(16):1999-2001. doi: 10.1182/blood-2016-08-732123. No abstract available.

24.

Multitarget selection of catalytic antibodies with β-lactamase activity using phage display.

Shahsavarian MA, Chaaya N, Costa N, Boquet D, Atkinson A, Offmann B, Kaveri SV, Lacroix-Desmazes S, Friboulet A, Avalle B, Padiolleau-Lefèvre S.

FEBS J. 2017 Feb;284(4):634-653. doi: 10.1111/febs.14012. Epub 2017 Feb 6.

25.

Summary report of the First International Conference on inhibitors in haemophilia A.

Lacroix-Desmazes S, Scott DW, Goudemand J, Van Den Berg M, Makris M, Van Velzen AS, Santagostino E, Lillicrap D, Rosendaal FR, Hilger A, Sauna ZE, Oldenburg J, Mantovani L, Mancuso ME, Kessler C, Hay CRM, Knoebl P, Di Minno G, Hoots K, Bok A, Brooker M, Buoso E, Mannucci PM, Peyvandi F.

Blood Transfus. 2017 Oct;15(6):568-576. doi: 10.2450/2016.0252-16. Epub 2016 Nov 25. No abstract available.

26.

The C1 and C2 domains of blood coagulation factor VIII mediate its endocytosis by dendritic cells.

Gangadharan B, Ing M, Delignat S, Peyron I, Teyssandier M, Kaveri SV, Lacroix-Desmazes S.

Haematologica. 2017 Feb;102(2):271-281. doi: 10.3324/haematol.2016.148502. Epub 2016 Oct 6.

27.

Key insights to understand the immunogenicity of FVIII products.

Goudemand J, Peyvandi F, Lacroix-Desmazes S.

Thromb Haemost. 2016 Aug 31;116 Suppl 1:S2-9. doi: 10.1160/TH16-01-0048. Epub 2016 Aug 16.

PMID:
27528279
28.

Innovating immune tolerance induction for haemophilia.

Batsuli G, Meeks SL, Herzog RW, Lacroix-Desmazes S.

Haemophilia. 2016 Jul;22 Suppl 5:31-5. doi: 10.1111/hae.12989. Review.

PMID:
27405673
29.

Generation of Catalytic Antibodies Is an Intrinsic Property of an Individual's Immune System: A Study on a Large Cohort of Renal Transplant Patients.

Mahendra A, Peyron I, Thaunat O, Dollinger C, Gilardin L, Sharma M, Wootla B, Rao DN, Padiolleau-Lefevre S, Boquet D, More A, Varadarajan N, Kaveri SV, Legendre C, Lacroix-Desmazes S.

J Immunol. 2016 May 15;196(10):4075-81. doi: 10.4049/jimmunol.1403005. Epub 2016 Apr 11.

30.

Relationship between natural and heme-mediated antibody polyreactivity.

Hadzhieva M, Vassilev T, Bayry J, Kaveri S, Lacroix-Desmazes S, Dimitrov JD.

Biochem Biophys Res Commun. 2016 Mar 25;472(1):281-6. doi: 10.1016/j.bbrc.2016.02.112. Epub 2016 Feb 27.

PMID:
26926563
31.

Heme: Modulator of Plasma Systems in Hemolytic Diseases.

Roumenina LT, Rayes J, Lacroix-Desmazes S, Dimitrov JD.

Trends Mol Med. 2016 Mar;22(3):200-213. doi: 10.1016/j.molmed.2016.01.004. Epub 2016 Feb 12. Review.

PMID:
26875449
32.

Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.

Dargaud Y, Pavlova A, Lacroix-Desmazes S, Fischer K, Soucie M, Claeyssens S, Scott DW, d'Oiron R, Lavigne-Lissalde G, Kenet G, Escuriola Ettingshausen C, Borel-Derlon A, Lambert T, Pasta G, Négrier C.

Haemophilia. 2016 Jan;22 Suppl 1:1-24. doi: 10.1111/hae.12860.

33.

Immunogenicity of long-lasting recombinant factor VIII products.

Ing M, Gupta N, Teyssandier M, Maillère B, Pallardy M, Delignat S, Lacroix-Desmazes S; ABIRISK consortium.

Cell Immunol. 2016 Mar;301:40-8. doi: 10.1016/j.cellimm.2015.12.006. Epub 2015 Dec 19. Review.

PMID:
26723503
34.

Neutralization of Japanese Encephalitis Virus by heme-induced broadly reactive human monoclonal antibody.

Gupta N, de Wispelaere M, Lecerf M, Kalia M, Scheel T, Vrati S, Berek C, Kaveri SV, Desprès P, Lacroix-Desmazes S, Dimitrov JD.

Sci Rep. 2015 Nov 6;5:16248. doi: 10.1038/srep16248.

35.

Antibody profile in Indian severe haemophilia A patients with and without FVIII inhibitors.

Pinto P, Shetty S, Lacroix-Desmazes S, Bayry J, Kaveri S, Ghosh K.

Immunol Lett. 2016 Jan;169:93-7. doi: 10.1016/j.imlet.2015.09.013. Epub 2015 Oct 1.

PMID:
26433059
36.

Natural and Induced Antibody Polyreactivity.

Jarossay A, Hadzhieva M, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Anticancer Agents Med Chem. 2015;15(10):1230-41.

PMID:
26179269
37.

Standardizing terms, definitions and concepts for describing and interpreting unwanted immunogenicity of biopharmaceuticals: recommendations of the Innovative Medicines Initiative ABIRISK consortium.

Rup B, Pallardy M, Sikkema D, Albert T, Allez M, Broet P, Carini C, Creeke P, Davidson J, De Vries N, Finco D, Fogdell-Hahn A, Havrdova E, Hincelin-Mery A, C Holland M, H Jensen PE, Jury EC, Kirby H, Kramer D, Lacroix-Desmazes S, Legrand J, Maggi E, Maillère B, Mariette X, Mauri C, Mikol V, Mulleman D, Oldenburg J, Paintaud G, R Pedersen C, Ruperto N, Seitz R, Spindeldreher S, Deisenhammer F; ABIRISK Consortium.

Clin Exp Immunol. 2015 Sep;181(3):385-400. doi: 10.1111/cei.12652. Epub 2015 Jul 2. Review.

38.

Materno-Fetal Transfer of Preproinsulin Through the Neonatal Fc Receptor Prevents Autoimmune Diabetes.

Culina S, Gupta N, Boisgard R, Afonso G, Gagnerault MC, Dimitrov J, Østerbye T, Justesen S, Luce S, Attias M, Kyewski B, Buus S, Wong FS, Lacroix-Desmazes S, Mallone R.

Diabetes. 2015 Oct;64(10):3532-42. doi: 10.2337/db15-0024. Epub 2015 Apr 27.

39.

Correction to Mechanism and functional implications of the heme-induced binding promiscuity of IgE.

Hadzhieva M, Vassilev TL, Roumenina LT, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Biochemistry. 2015 Apr 14;54(14):2399. doi: 10.1021/acs.biochem.5b00323. Epub 2015 Apr 3. No abstract available.

PMID:
25839915
40.

Mechanism and functional implications of the heme-induced binding promiscuity of IgE.

Hadzhieva M, Vassilev TL, Roumenina LT, Bayry J, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Biochemistry. 2015 Mar 24;54(11):2061-72. doi: 10.1021/bi501507m. Epub 2015 Mar 11. Erratum in: Biochemistry. 2015 Apr 14;54(14):2399.

PMID:
25742488
41.

Design of clinical trials for new products in hemophilia: communication from the SSC of the ISTH.

Dimichele DM, Lacroix-Desmazes S, Peyvandi F, Srivastava A, Rosendaal FR; Subcommittee on Factor VIII, Factor IX and Rare Coagulation Disorders.

J Thromb Haemost. 2015 May;13(5):876-9. doi: 10.1111/jth.12882. Epub 2015 Apr 13. No abstract available.

42.

Regulation of immune responses to protein therapeutics by transplacental induction of T cell tolerance.

Gupta N, Culina S, Meslier Y, Dimitrov J, Arnoult C, Delignat S, Gangadharan B, Lecerf M, Justesen S, Gouilleux-Gruart V, Salomon BL, Scott DW, Kaveri SV, Mallone R, Lacroix-Desmazes S.

Sci Transl Med. 2015 Feb 18;7(275):275ra21. doi: 10.1126/scitranslmed.aaa1957.

PMID:
25696000
43.

Alloantibodies to therapeutic factor VIII in hemophilia A: the role of von Willebrand factor in regulating factor VIII immunogenicity.

Oldenburg J, Lacroix-Desmazes S, Lillicrap D.

Haematologica. 2015 Feb;100(2):149-56. doi: 10.3324/haematol.2014.112821. Review.

44.

Prevalence and gene characteristics of antibodies with cofactor-induced HIV-1 specificity.

Lecerf M, Scheel T, Pashov AD, Jarossay A, Ohayon D, Planchais C, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

J Biol Chem. 2015 Feb 20;290(8):5203-13. doi: 10.1074/jbc.M114.618124. Epub 2015 Jan 6.

45.

Intravenous immunoglobulin and immune response.

Kaveri SV, Lecerf M, Saha C, Kazatchkine MD, Lacroix-Desmazes S, Bayry J.

Clin Exp Immunol. 2014 Dec;178 Suppl 1:94-6. doi: 10.1111/cei.12526. No abstract available.

46.

Haemarthrosis and arthropathy do not favour the development of factor VIII inhibitors in severe haemophilia A mice.

Peyron I, Dimitrov JD, Delignat S, Gangadharan B, Planchais C, Kaveri SV, Lacroix-Desmazes S.

Haemophilia. 2015 Jan;21(1):e94-8. doi: 10.1111/hae.12579. Epub 2014 Dec 4. No abstract available.

PMID:
25471131
47.

Role of coagulation-associated processes on factor VIII immunogenicity in a mouse model of severe hemophilia A.

Gangadharan B, Delignat S, Ollivier V, Gupta N, Mackman N, Kaveri SV, Lacroix-Desmazes S.

J Thromb Haemost. 2014 Dec;12(12):2065-9. doi: 10.1111/jth.12740. Epub 2014 Oct 25.

48.

Molecular basis for bacterial peptidoglycan recognition by LysM domains.

Mesnage S, Dellarole M, Baxter NJ, Rouget JB, Dimitrov JD, Wang N, Fujimoto Y, Hounslow AM, Lacroix-Desmazes S, Fukase K, Foster SJ, Williamson MP.

Nat Commun. 2014 Jun 30;5:4269. doi: 10.1038/ncomms5269.

49.

A cryptic polyreactive antibody recognizes distinct clades of HIV-1 glycoprotein 120 by an identical binding mechanism.

Dimitrov JD, Planchais C, Scheel T, Ohayon D, Mesnage S, Berek C, Kaveri SV, Lacroix-Desmazes S.

J Biol Chem. 2014 Jun 20;289(25):17767-79. doi: 10.1074/jbc.M114.556266. Epub 2014 May 6.

50.

Cryptic polyreactivity of IgG expressed by splenic marginal zone B-cell lymphoma.

Mahendra A, Gangadharan B, André S, Boudjoghra M, Davi F, Lecerf M, Planchais C, Kaveri SV, Lacroix-Desmazes S, Dimitrov JD.

Mol Immunol. 2014 Jul;60(1):54-61. doi: 10.1016/j.molimm.2014.03.009. Epub 2014 Apr 24.

PMID:
24769492

Supplemental Content

Loading ...
Support Center